OKYO Pharma Limited (OKYO) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 London, 영국. 현재 CEO는 Robert J. Dempsey.
OKYO 을(를) 보유 IPO 날짜 2022-05-17, 3 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $63.31M.
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
